Skip to main content
Top
Published in: World Journal of Surgical Oncology 1/2017

Open Access 01-12-2017 | Research

TPX2 expression is associated with poor survival in gastric cancer

Authors: Chiharu Tomii, Mikito Inokuchi, Yoko Takagi, Toshiaki Ishikawa, Sho Otsuki, Hiroyuki Uetake, Kazuyuki Kojima, Tatsuyuki Kawano

Published in: World Journal of Surgical Oncology | Issue 1/2017

Login to get access

Abstract

Background

Targeting protein for Xenopus kinesin-like protein 2 (TPX2) is a microtubule-associated protein required for microtubule formation in human cells. Several studies have demonstrated that TPX2 is overexpressed in multiple tumor types and promotes tumor growth and metastasis. However, there have been few reports regarding its role in gastric cancer. In this study, we evaluated TPX2 expression and investigated its correlations with gastric cancer clinicopathological features and prognosis.

Methods

Tumor samples were obtained from 290 patients with gastric adenocarcinoma who had undergone gastrectomy. The expression of TPX2 protein was examined using immunohistochemical staining. TPX2 messenger RNA (mRNA) levels were evaluated using real-time quantitative reverse transcription PCR in 19 of the gastric cancer tumors and adjacent normal tissues.

Results

The mRNA levels of TPX2 were significantly higher in gastric cancer tissues than in matched adjacent normal tissues (p = 0.004). In the immunohistochemical analysis, TPX2 overexpression was found in 123 (42.4%) of 290 patients. High TPX2 expression was positively associated with age, type of histology, depth of tumor, lymph node metastasis, stage, and remote metastasis or recurrence. High TPX2 expression was significantly associated with poorer disease-specific survival (p = 0.004) and relapse-free interval (p = 0.013).

Conclusions

Our results indicated that high TPX2 expression was associated with tumor progression and poor survival in gastric cancer.
Literature
1.
go back to reference Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.CrossRefPubMed Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.CrossRefPubMed
2.
go back to reference Hartqrink HH, Jansen EP, van Grieken NC, van de Velde CJ. Gastric cancer. Lancet. 2009;374:477–90.CrossRef Hartqrink HH, Jansen EP, van Grieken NC, van de Velde CJ. Gastric cancer. Lancet. 2009;374:477–90.CrossRef
3.
go back to reference Koizumi W, Takiuchi H, Yamada Y, Boku N, Fuse N, Muro K, et al. Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study). Ann Oncol. 2010;21:1001–5.CrossRefPubMed Koizumi W, Takiuchi H, Yamada Y, Boku N, Fuse N, Muro K, et al. Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study). Ann Oncol. 2010;21:1001–5.CrossRefPubMed
4.
go back to reference Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358:36–46.CrossRefPubMed Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358:36–46.CrossRefPubMed
5.
go back to reference Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215–21.CrossRefPubMed Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215–21.CrossRefPubMed
6.
go back to reference Lenqauer C, Kinzler KW, Voqelstein B. Genetic instabilities in human cancers. Nature. 1998;396:643–9.CrossRef Lenqauer C, Kinzler KW, Voqelstein B. Genetic instabilities in human cancers. Nature. 1998;396:643–9.CrossRef
7.
go back to reference Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet. 2006;38:1043–8.CrossRefPubMed Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet. 2006;38:1043–8.CrossRefPubMed
8.
go back to reference Gruss OJ, Wittmann M, Yokoyama H, Pepperkok R, Kufer T, Sillje H, et al. Chromosome-induced microtubule assembly mediated by TPX2 is required for spindle formation in HeLa cells. Nat Cell Biol. 2002;4:871–9.CrossRefPubMed Gruss OJ, Wittmann M, Yokoyama H, Pepperkok R, Kufer T, Sillje H, et al. Chromosome-induced microtubule assembly mediated by TPX2 is required for spindle formation in HeLa cells. Nat Cell Biol. 2002;4:871–9.CrossRefPubMed
10.
go back to reference Neumayer G, Belzil C, Gruss OJ, Nquyen MD. TPX2: of spindle assembly, DNA damage response, and cancer. Cell Mol Life Sci. 2014;71:3027–47.CrossRefPubMed Neumayer G, Belzil C, Gruss OJ, Nquyen MD. TPX2: of spindle assembly, DNA damage response, and cancer. Cell Mol Life Sci. 2014;71:3027–47.CrossRefPubMed
11.
go back to reference Ma Y, Lin D, Sun W, Xiao T, Yuan J, Han N, et al. Expression of targeting protein for xklp2 associated with both malignant transformation of respiratory epithelium and progression of squamous cell lung cancer. Clin Cancer Res. 2006;12:1121–7.CrossRefPubMed Ma Y, Lin D, Sun W, Xiao T, Yuan J, Han N, et al. Expression of targeting protein for xklp2 associated with both malignant transformation of respiratory epithelium and progression of squamous cell lung cancer. Clin Cancer Res. 2006;12:1121–7.CrossRefPubMed
12.
go back to reference Liang B, Jia C, Huang Y, He H, Li J, Liao H, et al. TPX2 level correlates with hepatocellular carcinoma cell proliferation, apoptosis, and EMT. Dig Dis Sci. 2015;60:2360–72.CrossRefPubMed Liang B, Jia C, Huang Y, He H, Li J, Liao H, et al. TPX2 level correlates with hepatocellular carcinoma cell proliferation, apoptosis, and EMT. Dig Dis Sci. 2015;60:2360–72.CrossRefPubMed
13.
go back to reference Wei P, Zhang N, Xu Y, Li X, Shi D, Wang Y, et al. TPX2 is a novel prognostic marker for the growth and metastasis of colon cancer. J Transl Med. 2013;11:313.CrossRefPubMedPubMedCentral Wei P, Zhang N, Xu Y, Li X, Shi D, Wang Y, et al. TPX2 is a novel prognostic marker for the growth and metastasis of colon cancer. J Transl Med. 2013;11:313.CrossRefPubMedPubMedCentral
14.
go back to reference Huanq Y, Guo W, Kan H. TPX2 is a prognostic marker and contributes growth and metastasis of human hepatocellular carcinoma. Int J Mol Sci. 2014;15:18148–61.CrossRef Huanq Y, Guo W, Kan H. TPX2 is a prognostic marker and contributes growth and metastasis of human hepatocellular carcinoma. Int J Mol Sci. 2014;15:18148–61.CrossRef
15.
go back to reference Warner SL, Stephens BJ, Nwokenkwo S, Hostetter G, Sugeng A, Hidalgo M, et al. Validation of TPX2 as a potential therapeutic target in pancreatic cancer cells. Clin Cancer Res. 2009;15:6519–28.CrossRefPubMedPubMedCentral Warner SL, Stephens BJ, Nwokenkwo S, Hostetter G, Sugeng A, Hidalgo M, et al. Validation of TPX2 as a potential therapeutic target in pancreatic cancer cells. Clin Cancer Res. 2009;15:6519–28.CrossRefPubMedPubMedCentral
16.
go back to reference Sillars-Hardebol AH, Carvalho B, Tijssen M, Belien JA, de Wit M, Delis-van Diemen PM, et al. TPX2 and AURKA promote 20q amplicon-driven colorectal adenoma to carcinoma progression. Gut. 2012;61:1568–75.CrossRefPubMed Sillars-Hardebol AH, Carvalho B, Tijssen M, Belien JA, de Wit M, Delis-van Diemen PM, et al. TPX2 and AURKA promote 20q amplicon-driven colorectal adenoma to carcinoma progression. Gut. 2012;61:1568–75.CrossRefPubMed
17.
go back to reference Shigeishi H, Ohta K, Hiraoka M, Fujimoto S, Minami M, Higashikawa K, Kamata N. Expression of TPX2 in salivary gland carcinomas. Oncol Rep. 2009;21:341–4.PubMed Shigeishi H, Ohta K, Hiraoka M, Fujimoto S, Minami M, Higashikawa K, Kamata N. Expression of TPX2 in salivary gland carcinomas. Oncol Rep. 2009;21:341–4.PubMed
18.
go back to reference Chang H, Wang J, Tian Y, Xu J, Gou X, Cheng J. The TPX2 gene is a promising diagnostic and therapeutic target for cervical cancer. Oncol Rep. 2012;27:1353–9.PubMed Chang H, Wang J, Tian Y, Xu J, Gou X, Cheng J. The TPX2 gene is a promising diagnostic and therapeutic target for cervical cancer. Oncol Rep. 2012;27:1353–9.PubMed
19.
go back to reference Liang B, Zheng W, Fang L, Wu L, Zhou F, Yin X, et al. Overexpressed targeting protein for Xklp2 (TPX2) serves as a promising prognostic marker and therapeutic target for gastric cancer. Cancer Biol Ther. 2016;17:824–32.CrossRefPubMed Liang B, Zheng W, Fang L, Wu L, Zhou F, Yin X, et al. Overexpressed targeting protein for Xklp2 (TPX2) serves as a promising prognostic marker and therapeutic target for gastric cancer. Cancer Biol Ther. 2016;17:824–32.CrossRefPubMed
20.
go back to reference Aquirre-Portoles C, Bird AW, Hyman A, Canamero M, Perez de Castro I, Malumbres M. Tpx2 controls spindle integrity, genome stability, and tumor development. Cancer Res. 2012;72:1518–28.CrossRef Aquirre-Portoles C, Bird AW, Hyman A, Canamero M, Perez de Castro I, Malumbres M. Tpx2 controls spindle integrity, genome stability, and tumor development. Cancer Res. 2012;72:1518–28.CrossRef
21.
go back to reference Miwa T, Kokuryo T, Yokoyama Y, Yamaguchi J, Nagino M. Therapeutic potential of targeting protein for Xklp2 silencing for pancreatic cancer. Cancer Med. 2015;4:1091–100.CrossRefPubMedPubMedCentral Miwa T, Kokuryo T, Yokoyama Y, Yamaguchi J, Nagino M. Therapeutic potential of targeting protein for Xklp2 silencing for pancreatic cancer. Cancer Med. 2015;4:1091–100.CrossRefPubMedPubMedCentral
22.
go back to reference Satow R, Shitashige M, Kanai T, Takeshita F, Ojima H, Jigami T, et al. Combined functional genome survey of therapeutic targets for hepatocellular carcinoma. Clin Cancer Res. 2010;16:2518–28.CrossRefPubMed Satow R, Shitashige M, Kanai T, Takeshita F, Ojima H, Jigami T, et al. Combined functional genome survey of therapeutic targets for hepatocellular carcinoma. Clin Cancer Res. 2010;16:2518–28.CrossRefPubMed
23.
go back to reference Bian M, Fu J, Yan Y, Chen Q, Yang C, Shi Q, et al. Short exposure to paclitaxel induces multipolar spindle formation and aneuploidy through promotion of acentrosomal pole assembly. Sci China Life Sci. 2010;53:1322–9.CrossRefPubMed Bian M, Fu J, Yan Y, Chen Q, Yang C, Shi Q, et al. Short exposure to paclitaxel induces multipolar spindle formation and aneuploidy through promotion of acentrosomal pole assembly. Sci China Life Sci. 2010;53:1322–9.CrossRefPubMed
24.
go back to reference Niu H, Manfredi M, Ecsedy JA. Scientific rationale supporting the clinical development strategy for the investigational Aurora A kinase inhibitor alisertib in cancer. Front Oncol. 2015;5:189.CrossRefPubMedPubMedCentral Niu H, Manfredi M, Ecsedy JA. Scientific rationale supporting the clinical development strategy for the investigational Aurora A kinase inhibitor alisertib in cancer. Front Oncol. 2015;5:189.CrossRefPubMedPubMedCentral
Metadata
Title
TPX2 expression is associated with poor survival in gastric cancer
Authors
Chiharu Tomii
Mikito Inokuchi
Yoko Takagi
Toshiaki Ishikawa
Sho Otsuki
Hiroyuki Uetake
Kazuyuki Kojima
Tatsuyuki Kawano
Publication date
01-12-2017
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2017
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/s12957-016-1095-y

Other articles of this Issue 1/2017

World Journal of Surgical Oncology 1/2017 Go to the issue